Building A Robust Cell And Gene Therapy Supply Chain

By Travis Ott, Senior Manager, Single-Use Set (SUS) & Supply Chain, Invetech

Current supply chains support distinct automated CGT manufacturing elements when they are well-characterized and integrated into commercial manufacturing. As cell therapies develop and become more commercialized, manufacturers must adopt a sophisticated supply chain that provides the necessary materials and technologies to support therapeutic development.

Once a CGT manufacturing process is registered with regulatory authorities, it’s difficult and expensive to change it. CGT manufacturers must ensure their supply chain can support the manufacturing process.

In this blog we review how CGT manufacturers can identify suppliers, avoid shortages and incorporate cost savings to build a successful supply chain.